A Nine-Year Investigation of Industry Research and Nonresearch Payments to Emergency Physicians in the United States Between 2014 and 2022

Murayama, Anju

doi:10.1016/j.jemermed.2023.10.026

Cited by 7 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 94 , 95 , 96 , 97 , 98 , 99 This legislation ensures that manufacturers report all research payments to physicians through third parties such as universities and teaching hospitals. 100 , 101 , 102 , 103 Some professional medical societies in the United States, including the American Society of Clinical Oncology and the American Gastroenterological Association, use this database to verify the accuracy of COI declarations by CPG authors. 25 , 104…”

Section: Discussionmentioning

confidence: 99%

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Murayama,

Aizawa,

Byreddy

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

Background Clinical practice guidelines (CPGs) offer disease management recommendations based on scientific evidence. However, financial conflicts of interest between CPG developers and the pharmaceutical industry could bias these recommendations, potentially affecting patient care. Proper management of these conflicts of interest is particularly crucial for maintaining the integrity of CPGs. The study aimed to evaluate the extent of financial relationships between the pharmaceutical industry and authors of CPGs for cardiovascular diseases in Japan. Methods and Results The study analyzed personal payments from the pharmaceutical industry to authors of cardiovascular disease CPGs published by the Japanese Circulation Society from January 2015 to December 2022. Payment data, including speaking, consultancy, and writing fees from 2016 to 2020, were extracted from a publicly available database containing personal payments disclosed by all major pharmaceutical companies. A total of 929 unique authors from 37 eligible Japanese Circulation Society CPGs were identified. Notably, 94.4% of these authors received personal payments from pharmaceutical companies, totaling >US $70.8 million. The mean±SD payment per author was US $76 314±138 663) and the median payment per author was US $20 792 (interquartile range: US $4262–US $76 998) over the 5‐year period. Chairs of CPGs received significantly higher payments than other authors. More than 80% of authors in each CPG received personal payments. Conclusions The study elucidated that there were considerable financial relationships between pharmaceutical companies and cardiology CPG authors in Japan. This finding deviates from international conflict of interest management policies, suggesting the need for more stringent conflict of interest management strategies by the Japanese Circulation Society to ensure the development of trustworthy and evidence‐based CPGs.

show abstract

Section: Discussionmentioning

confidence: 99%

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Murayama,

Aizawa,

Byreddy

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…When compared to previous studies using similar methodologies, a higher proportion of gastroenterologists and hepatologists received research payments than physicians in other specialties. For instance, the proportions of physicians receiving research payments were approximately 1.2% in emergency medicine [13], 7% in urology [24], 11% in neurosurgery [6], 12% in nephrology [10], 13% in endocrinology [11], 14% in pulmonology [4], and 15.0% in infectious diseases [8], while 20.2% in rheumatology [9]. Moreover, the per-physician annual amounts of associated research payments were moderate when compared to other specialties, ranging from $26,724 to $38,271.…”

Section: Discussionmentioning

confidence: 99%

“…The healthcare industry predominantly directs its research payments toward conducting clinical trials to assess the safety and efficacy of medical products, particularly to obtain drug approvals or expand their indications to other diseases. Meanwhile, previous studies showed that there were fewer research payments to physicians from the healthcare industry in other specialties, such as emergency medicine, urology, and neurosurgery, where there were fewer novel drugs [6,13,24]. Thus, the large research funding for gastroenterologists and hepatologists could have been supported by the growing number of novel and effective drugs in the fields of gastroenterology and hepatology.…”

Section: Discussionmentioning

confidence: 99%

“…This figure may underestimate the true extent of research payments provided to gastroenterologists and hepatologists in the healthcare industry. Previous studies have indicated that many healthcare companies channel their research payments to physicians through teaching hospitals and research institutions [4][5][6][7][8][9][10][11][12][13]. For example, the healthcare industry spent over $799.9 million on pulmonologists for research purposes in the United States [4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Industry-Sponsored Research Payments to Gastroenterologists and Hepatologists in the United States Between 2014 and 2021

Murayama

2023

Cureus

Self Cite

View full text Add to dashboard Cite

This cross-sectional study aimed to examine the scale and trends of industry-sponsored research payments to gastroenterologists and hepatologists in the United States from 2014 to 2021. MethodsUsing the Open Payments Database and the National Plan and Provider Enumeration System (NPPES), the study analyzed both grant and research payments made to individual gastroenterologists and associated payments made for research where gastroenterologists and hepatologists served as principal investigators. ResultsAfter adjusting for inflation, the study found that a total of $1.5 billion was allocated to gastroenterologists by 284 companies during this period. Only 15.9% of the 20,986 gastroenterologists received at least one research payment, with associated research payments accounting for 97.6% of all payments. The study also revealed a significant increase in the number of gastroenterologists receiving associated research payments and a more than twofold increase in payments for registered clinical trials from 2014 to 2021. ConclusionThe healthcare industry allocated large amounts of research funding to gastroenterologists and hepatologists. The study underscores the critical role of industry-sponsored clinical trials in advancing gastroenterological research and treatments.Categories: Gastroenterology, Public Health Keywords: clinical research education, financial conflicts of interest, conflicts of interest, united states of america, united states, sunshine act, physician payment sunshine act, open payments database, industry payment, research payment

show abstract

“…To quote the AAMC’s definition of active physicians, “physicians…who have not completed their graduate medical education are excluded.” Fourth, the AAMC report did not include all specialties and stated that “this report presents data for the practice specialties with the largest number of active physicians in 2021, meaning more than 2,500 active physicians.” Fifth, the AAMC’s report included only physicians who were working more than 20 hours per week, a restriction not imposed in our analysis . Sixth, it is important to note that previous reports based on the National Plan and Provider Enumeration System (NPPES) database often reported estimates higher than those provided by the AAMC . Because we do not have access to the Masterfile underlying the AAMC’s reported data, we are unable to explain the reason for differences between the NPPES and AAMC numbers.…”

mentioning

confidence: 88%

Industry Payments to Physicians

Sayed,

Foy

2024

JAMA

View full text Add to dashboard Cite

A Nine-Year Investigation of Industry Research and Nonresearch Payments to Emergency Physicians in the United States Between 2014 and 2022

Cited by 7 publications

References 45 publications

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Industry-Sponsored Research Payments to Gastroenterologists and Hepatologists in the United States Between 2014 and 2021

Industry Payments to Physicians

Contact Info

Product

Resources

About